The antigen-binding region of an antibody (IgG) consists of several complementarity-determining regions (CDRs). Therapeutic Antibody Drugs, such as ADCs, typically utilize isolated CDR1 or CDR3 domains from the antibody variable region to conjugate with drug molecules, enabling specific in vivo targeting, such as cancer cell recognition. Anti-idiotypic Antibodies specifically recognize and bind to these variable regions (i.e., the CDRs) of another antibodies.

Utilizing our advanced Phage Display technology, KMD offers integrated Anti-idiotypic Antibody Services. Starting from samples like gene synthesis products, hybridoma cell lines, or peripheral blood lymphocytes, we construct diverse Phage Display Antibody Libraries (Naive, Semi-synthetic, Dully Synthetic) with high complexity (~10¹¹ independent clones, ~10¹⁰ functional clones). We then screen these libraries to isolate Monoclonal Antibodies exhibiting High Specificity and Affinity for the target antigen (idiotope). 

High-affinity Anti-idiotypic Antibody gene fragments identified through screening are cloned into our proprietary Phagemid Expression System using PCR. This versatile system allows for High-level Expression of the Anti-idiotypic Antibodies in phage, prokaryotic, and mammalian expression platforms.

I. Antigen-Neutralizing Type

II. Antigen-Neutralizing Type

III. Drug-Target Complex Type